Adverse event reporting timelines

Under Regulation (EU) 2019/6, all adverse events must be recorded in the Union Pharmacovigilance Database within 30 calendar days. There is no longer a faster track for serious cases and a slower one for the rest — the single timeline applies across the board.

• It covers serious and non-serious events alike.
• It covers animal, human, and environmental adverse events, and lack of efficacy (LOE).
• Calendar days, not working days — weekends and holidays count.

An Emerging Safety Issue (ESI) is information that may influence the benefit-risk balance of a product and could require urgent regulatory action. ESIs sit outside the 30-day rule entirely.

• They must be notified without delay, and no later than 3 working days after identification.
• Examples include a possible new serious risk, a clinically significant change in frequency or severity, or a finding that could affect the benefit-risk balance.
• The decision to escalate is a judgement call — which is exactly why a clear internal triage step matters.

This is where compliant-on-paper systems fail in practice. Day 0 is the day any employee of the organisation first becomes aware of the case — not the day it reaches the safety department.

• "Anyone" includes field representatives, technical support, and call-centre staff.
• If a sales rep hears about a reaction on a Monday, the clock started on Monday — even if the safety team only sees it the following week.
• The practical consequence: everyone who might receive a report needs a fast, known route to forward it the same day.

A report only becomes a valid Individual Case Safety Report (ICSR) once four minimum elements are present. Until then, the case is incomplete and follow-up must be initiated.

• An identifiable reporter.
• An identifiable patient — species is mandatory.
• A suspect veterinary medicinal product.
• At least one adverse event.

Crucially, a confirmed causal relationship is not required to report. Suspicion is enough — causality is assessed, it is not a gate that holds up the timeline.

For companies operating across markets, the timelines diverge and must be tracked separately.

• EU — 30 calendar days for all AEs; 3 working days for ESIs.
• UK — all worldwide AEs for UK-authorised products within 30 days; Northern Ireland cases go to both the VMD and the EMA.
• USA (FDA) — 15 days for serious and unexpected AEs; a 3-day Field Alert for product defects.
• Canada & Australia — the 15-day timeline applies to serious and unexpected cases.

Reporting timelines are binding, and inspectors treat them as a bellwether for the health of the whole system.

• Late reporting of serious unexpected AEs is consistently classified as a Critical deficiency in PV inspections.
• A single late case rarely stands alone in a finding — it points to a weak intake process, which is what gets scrutinised.
• The fix is structural: a defined intake channel, same-day forwarding from all staff, and a clock that starts at first awareness.